GSK Plc (GLAXF)
25.25
-0.25
(-0.98%)
USD |
OTCM |
Jun 16, 16:00
GSK Cash from Operations (Quarterly) : 1.483B for March 31, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 1.483B |
| December 31, 2025 | 2.682B |
| September 30, 2025 | 3.015B |
| June 30, 2025 | 2.594B |
| March 31, 2025 | 1.422B |
| December 31, 2024 | 2.655B |
| September 30, 2024 | 2.783B |
| June 30, 2024 | 1.113B |
| March 31, 2024 | 1.191B |
| December 31, 2023 | 3.686B |
| September 30, 2023 | 2.785B |
| June 30, 2023 | 1.353B |
| March 31, 2023 | 115.43M |
| December 31, 2022 | 1.856B |
| September 30, 2022 | 1.201B |
| June 30, 2022 | 1.628B |
| March 31, 2022 | 3.310B |
| December 31, 2021 | 4.563B |
| September 30, 2021 | 3.452B |
| June 30, 2021 | 1.356B |
| March 31, 2021 | 336.45M |
| December 31, 2020 | 4.662B |
| September 30, 2020 | 1.068B |
| June 30, 2020 | 2.964B |
| March 31, 2020 | 1.151B |
| Date | Value |
|---|---|
| December 31, 2019 | 4.014B |
| September 30, 2019 | 3.026B |
| June 30, 2019 | 1.375B |
| March 31, 2019 | 741.04M |
| December 31, 2018 | 4.924B |
| September 30, 2018 | 2.614B |
| June 30, 2018 | 1.509B |
| March 31, 2018 | 1.144B |
| December 31, 2017 | 3.351B |
| September 30, 2017 | 2.454B |
| June 30, 2017 | 934.65M |
| March 31, 2017 | 1.332B |
| December 31, 2016 | 3.321B |
| September 30, 2016 | 2.288B |
| June 30, 2016 | 1.464B |
| March 31, 2016 | 622.24M |
| December 31, 2015 | 1.829B |
| September 30, 2015 | 650.39M |
| June 30, 2015 | -58.23M |
| March 31, 2015 | 488.89M |
| December 31, 2014 | 3.060B |
| September 30, 2014 | 2.018B |
| June 30, 2014 | 910.61M |
| March 31, 2014 | 1.413B |
| December 31, 2013 | 3.114B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| AstraZeneca PLC | 3.420B |
| Haleon Plc | -- |
| ANI Pharmaceuticals, Inc. | 58.38M |
| Corcept Therapeutics, Inc. | -16.77M |
| Assertio Holdings, Inc. | 8.563M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -1.784B |
| Cash from Financing (Quarterly) | 229.06M |
| Free Cash Flow | 5.771B |
| Free Cash Flow Per Share (Quarterly) | 0.2176 |
| Free Cash Flow to Equity (Quarterly) | -408.28M |
| Free Cash Flow to Firm (Quarterly) | 1.080B |
| Free Cash Flow Yield | 5.58% |